Catalyzing Sarcopenia Drug Development: Identifying Outcomes, Defining Disease
This article was originally published in Pharmaceutical Approvals Monthly
FDA’s patient-focused drug development initiative and its Drug Development Tool for qualifying endpoints are galvanizing efforts to establish sarcopenia as an indication for clinical development in what could be a very significant market of elderly patients with weakness and functional disability.
You may also be interested in...
Companies developing treatments for sarcopenia ‘have no idea what they're doing’, according to Ray Lipicky, a former director of the FDA’s Cardio-Renal Drug Products Division who spoke as a patient at the US agency’s sarcopenia drug development meeting.
Volumetric imaging gains favor as a primary endpoint, along with single-arm studies, potentially creating a faster path to drug approval in the rare disease.
Biologics affecting myostatin signaling are at the forefront of the R&D pipeline for sarcopenia, with leading candidates in Phase II from Sanofi/Regeneron, Lilly and Novartis.